调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效观察

《调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、调强放射治疗同步替吉奧治疗高龄食管癌患者的疗效观察【摘要】目的：探讨常规分割调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效。方法：选择2011年10月-2013年10月门诊和住院治疗的高龄管癌患者53例。根据治疗模式不同，分为同步组和对照组，同步组采用调强放射治疗同步替吉奥治疗，对照组采用单纯调强放射治疗。结果：同步组较对照组的副反应略高，但差异无统计学意义（P>0.05）；同步组和对照组患者总有效率分别达到84.00%和57.14%,差异有统计学意义（P=0.033）;同步组和对照组患者12个月随访期内的中位无进展生存期分别为

2、10.84个月和9.36个月，差异有统计学意义（P=0.044），同步组和对照组患者的1年生存率分别为88.0%和85.7%,差异无统计学意义（P=0.75）。结论：调强放射治疗同步替吉奥治疗高龄食管癌患者的疗效肯定。【关键词】调强放疗；替吉奥；食管癌中图分类号R735.1文献标识码A文章编号1674-6805（2015）9-0004-03ClinicalAnalysisofElderlyEsophagealCancerPatientsTreatedwithIntensityModulatedRadiationTherapyan

3、dTegafurGimeracilOteracilPotassiumCapsule/WANGWu-long,WANGChun-lei,YUBai-qing,etal.//ChineseandForeignMedicalResearch,2015,13(9)：4-6【Abstract】Objective:Tostudytheclinicalanalysisofelderlyesophagealcancerpatientstreatedwithintensitymodulatedradiationtherapy(IMRT)andTe

4、gafurGimeracilOteracilPotassiumCapsule.Method：53elderlyesophagealcancerpatientsfromOctober2011toOctober2013wereselected.Accordingtothedifferenttreatmentmodalities，theyweredividedintothesynchronouschemotherapygroupandthecontrolgroup，thesynchronouschemotherapygroupwast

5、reatedwithIMRTandTegafurGimeracilOteracilPotassiumCapsule,thecontrolgroupwastreatedwithIMRT.Result:Thesideeffectsofthesynchronouschemotherapygroupwashigherthanthatofthecontrolgroup，butthedifferencehadnosignificantdifferencebetweentwogroups(P〉0.05);thetotaleffectivera

6、teofthesynchronouschemotherapygroupwas84.00%,thecontrolgroupwas57.14%，therewasstatisticallysignificantdifference(P=0.033)，themedianprogressionfreesurvivalofthesynchronouschemotherapygroupandcontrolgroupwere10.84monthsand9.36months，therewasstatisticallysignificantdiff

7、erence(P=0.044)，thesurvivalrateinoneyearofthesynchronouschemotherapygroupandcontrolgroupwere88.0%and85.7%，therewasnostatisticallysignificantdifference(P二0.75).Conclusion：EffectivenessofelderlyesophagealcancerpatientstreatedwithIMRTandTegafurGimeracilOteracilPotassium

8、Capsuleisdefinite.【Keywords】Intensitymodulatedradiationtherapy；TegafurGimeracilOteracilPotassiumCapsule；EsophagealcancerFirst-autho